27 November 2019
The 13th International Brain Tumour Awareness Week was held from Saturday, 26th October to Saturday, 2nd November 2019.
As part of this, the Children’s Brain Tumour Drug Delivery Consortium (CBTDDC) ran a series of articles on individuals working in very different capacities within the brain tumour field. Here we provide a taster of this coverage. You can read the full-length articles here: http://www.cbtddc.org/news/brain-tumour-awareness-week-2019.aspx
Nicola Farrer from the University of Oxford describes her lab’s work in the field of metals in medicine, designing new treatments and ways of delivering these treatments using physical activation methods. Nicola also talks about how she benefitted from the CBTDDC’s first Workshop on Drug Delivery to the Brain. Our second workshop is open for registrations – http://www.cbtddc.org/workshop/index.aspx
Sharon Kane, CEO of charity Funding Neuro, talks of how she was inspired to do everything she could to support the clinicians and researchers to try and find a treatment for brain tumours. Funding Neuro is part-funding a clinical trial using convection-enhanced delivery to deliver a combination therapy directly into Diffuse Intrinsic Pontine Gliomas.
Ruman Rahman from the University of Nottingham describes his optimism for future advances in the development of innovative ways to deliver more effective doses of new drugs into the brain. He also notes how the CBTDDC benefitted his own research team by helping to initiate a collaboration with researchers at Johns Hopkins University (USA).
Miroslaw Janowski from the University of Maryland discusses his work within the Society for Image Guided Neurointerventions (SIGN), set up to foster therapies of brain and spinal cord disorders while preventing toxicity to the rest of the body. Miroslaw also discusses SIGN’s collaboration with CBTDDC in developing and delivering the annual SIGN conference.
Cesare Spadoni tells his tale from a parent’s perspective, how losing his daughter to cancer led him to set up the charity aPODD (accelerating Paediatric Oncology Drug Development). Cesare’s next step took him into biotech, where he co-founded Oncoheroes Biosciences to focus exclusively on childhood cancer drug development.
David Walker, Chair of the CBTDDC at the University of Nottingham, talks about how we are now seeing a change in attitude and awareness of the importance of drug delivery in brain tumours, and the role that the CBTDDC is playing in this exciting research climate.